A new scientific breakthrough is raising hope that Alzheimer’s disease may someday be stopped rather than simply slowed. Researchers at the Indiana University School of Medicine have identified a promising drug target that attacks the disease from multiple angles at once. Their discovery focuses on an enzyme called IDOL, which appears to play a central role in the buildup of toxic brain plaques and the genetic risks that drive Alzheimer’s progression.
More than 7 million Americans currently live with Alzheimer’s disease, and that number is expected to nearly double by 2050. Scientists have been racing to find treatments that do more than temporarily stabilize symptoms. This new approach could represent a major shift in how the disease is treated.
The Scientists Behind the Breakthrough
The research was led by Dr. Hande Karahan and Dr. Jungsu Kim at Indiana University School of Medicine. Their findings were published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Kim described the discovery as a major step forward. He said, “What makes this exciting is that we now have a specific target that could lead to a new type of treatment.”
The work is part of a broader effort by Indiana University’s Alzheimer’s research programs, including the TREAT-AD drug discovery center, which brings together academic researchers and pharmaceutical expertise to accelerate the development of new therapies.
What the Drug Targets and Why It Matters
Instead of directly clearing plaques like current Alzheimer’s drugs, the new strategy targets the IDOL enzyme inside brain neurons.
This matters because IDOL controls levels of receptors involved in lipid metabolism and neuronal communication. When researchers removed or blocked this enzyme in experimental models, several important changes occurred at the same time.
Amyloid plaque buildup dropped significantly. Levels of APOE decreased, including APOE4, the strongest genetic risk factor for late onset Alzheimer’s disease. Receptors that support healthy brain communication increased. Neurons showed improved connectivity and resilience.
Karahan explained why this dual effect could be so important for patients. She said, “Not only decreasing amyloid levels but also increasing resilience to these pathological changes could maximize clinical benefits.”
How Effective the Results Were
The research used animal models of Alzheimer’s disease in which the IDOL gene was deleted specifically in brain neurons.
The results showed that neuronal IDOL deletion reduced amyloid accumulation and altered brain LDL receptor and APOE levels. The study also found increased levels of Reelin receptors, which are important for synaptic function and communication between neurons.
Single cell genetic analysis confirmed significant improvements in pathways related to synaptic organization.
One of the most important findings was that targeting neurons, rather than immune cells in the brain, produced the strongest benefit. Scientists had originally expected microglia, the brain’s immune cells, to play the largest role in plaque removal. Instead, neurons turned out to be the key.
Researchers believe this multi layered impact is what could allow the disease to be frozen in place rather than simply slowed.
How This Differs From Existing Alzheimer’s Drugs
The U.S. Food and Drug Administration has already approved two disease modifying Alzheimer’s drugs, lecanemab and donanemab. These treatments remove amyloid plaques and can stabilize patients at their current level of function.
However, the new IDOL strategy goes further by strengthening the brain’s ability to function even when plaques are present.
Scientists describe it as not only removing the trash from the brain but also improving the building’s structural integrity. By improving lipid metabolism and neuronal communication, the therapy could help maintain cognition longer.
The fact that IDOL is an enzyme also makes it attractive for drug development. Enzymes have well defined binding sites where medications can attach.
Kim explained, “Targeting enzymes in drug development offers key advantages due to their well defined active sites or pockets where drugs can attach and block their activity. This precision means we can design molecules that hit the right target with minimal side effects.”
When the Drug Could Become Available
At this stage, the therapy is still in the research and preclinical development phase. Scientists have not yet produced a finished drug for human use.
The next steps include designing molecules that inhibit the IDOL enzyme, testing safety, and evaluating whether the treatment preserves synaptic connections and reduces tau pathology, another major driver of Alzheimer’s disease.
Researchers are also studying whether this approach could eventually lead to an oral medication.
Because the discovery is still preclinical, widespread availability is likely several years away, depending on how quickly development and clinical trials progress.
What Experts Are Saying
Scientists involved in the research believe the discovery could open an entirely new treatment pathway.
Karahan said, “Targeting neuronal IDOL may offer multiple therapeutic benefits in Alzheimer’s disease by simultaneously reducing amyloid burden while enhancing neuroprotective effects.”
The broader Alzheimer’s research community is also optimistic about the potential of new targets emerging from the Indiana University programs. Alan Palkowitz, who leads the TREAT-AD center, said recent progress is helping create “a pathway for next generation clinical studies.”
A New Direction in the Fight Against Alzheimer’s
For decades, Alzheimer’s treatments have struggled to produce meaningful long term improvements. The discovery of the IDOL enzyme’s role suggests scientists may finally have found a way to attack the disease from several angles at once.
If future drugs can safely block this enzyme in humans, the approach could move medicine closer to a long sought goal. Instead of watching memory decline over time, doctors may someday be able to hold the disease in place and preserve brain function for years longer than currently possible.
While more research is needed, this breakthrough offers genuine hope that Alzheimer’s disease may not always be an unstoppable condition.
HNZ Editor: I know this seems a bit light on details, would love to know the end effects and the regimen. But the upshot is and that Indiana University is doing unique work.
